Novateor Research Laboratories Ltd (NOVATEOR) — shareholding pattern, promoter holding, financials and share price
About Novateor Research Laboratories Ltd (NOVATEOR)
Novateor Research Laboratories Ltd operates in the Personal Care industry, within the Fast Moving Consumer Goods sector. It trades on the NSE as NOVATEOR and on the BSE under scrip code 542771. Its ISIN is INE08JY01013.
Incorporated in 2011, Novateor Research Laboratories Ltd is in the business of Oral Care and Personal Care products. [1]
Novateor Research Laboratories Limited develops innovative personal care products with a focus on novel solutions. It has a well-equipped manufacturing facility in Ahmedabad, utilizing semi-automation for efficiency.
The company offers unique Tooth Whitening products under the brand 'SmiloShine', marking a pioneering entry in India's market with FDCA approval.
Listed peers in Personal Care: Thrive Future Habitats Limited, Ravelcare Ltd, JHS Svendgaard Laboratories Ltd, Mohini Health & Hygiene Ltd, Paramount Cosmetics (India) Ltd.
Valuation & Returns
At ₹32.8 a share, Novateor Research Laboratories Ltd (NOVATEOR) was valued at a price-to-earnings ratio of 198.8x against an industry P/E of 46.1x and a price-to-book of 1.78x on a book value of ₹18.51 per share. Solomo computes return on equity of 0.88% and return on capital employed of 1.59% from filed results.
- P/E
- 198.8x
- Industry P/E
- 46.1x
- P/B
- 1.78x
- EPS (TTM)
- ₹0.14
- Book value / share
- ₹18.51
- ROE
- 0.88%
- ROCE
- 1.59%
- ROA
- 0.7%
- Debt / equity
- 0.09x
- Dividend yield
- 0%
- EBITDA margin
- 9.92%
- 52-week range
- ₹20.08 – ₹51.77
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Novateor Research Laboratories Ltd (NOVATEOR) reported revenue of ₹3.83 crore, net profit of ₹0.1 crore and earnings per share of ₹0.17. That compares with revenue of ₹2.78 crore and net profit of ₹0.08 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1.36 crore and net profit ₹0.12 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 0.74 | 1.26 | 1.21 | 2.78 | 3.83 |
| Net profit (₹ cr) | -0.23 | 0.04 | 0.03 | 0.08 | 0.1 |
| EPS (₹) | -0.48 | 0.08 | 0.06 | 0.17 | 0.17 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 44.84% | 47.73% | 55.27% | 129.75% |
| Profit growth | 91.30% | - | - | 166.67% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 50.75% of Novateor Research Laboratories Ltd (NOVATEOR). Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2019.
Largest disclosed public shareholders in Mar 2026: JITIN JAYSUKHLAL DOSHI 8.03%, SHAH INVESTOR'S HOME LIMITED 2.48%, PREETI JITIN DOSHI 2.18%, RUSHABH JITIN DOSHI 2.08%, JAYSUKHLAL SHANTILAL DOSHI 1.88%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 50.75% | - | - | - | 49.25% |
| Sep 2025 | 50.9% | - | - | - | 49.1% |
| Mar 2025 | 60.87% | - | - | - | 39.13% |
| Sep 2024 | 60.87% | - | - | - | 39.13% |
| Mar 2024 | 60.87% | - | - | - | 39.13% |
| Sep 2023 | 60.87% | - | - | - | 39.13% |
| Mar 2023 | 60.87% | - | - | - | 39.13% |
| Sep 2022 | 60.87% | - | - | - | 39.13% |